ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 12, 2010, Pages 4422-4432

  Xu, Baihua ^a,b,c   Feng, Yan ^b   Lv, Binhua ^a,b,c   Xu, Ge ^b   Zhang, Lili ^b   Du, Jiyan ^b   Peng, Kun ^b   Xu, Min ^b   Dong, Jiajia ^b   Zhang, Wenbin ^b   Zhang, Ting ^b   Zhu, Liangcheng ^b   Ding, Haifeng ^b   Sheng, Zelin ^b   Welihinda, Ajith ^d   Seed, Brian ^d   Chen, Yuanwei ^a,b  

^a CHENGDU INSTITUTE OF ORGANIC CHEMISTRY   (China)

^b Egret Pharma (Shanghai) Limited   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d Theracos Inc   (United States)

Author keywords

Blood glucose; Diabetes; ortho Substituted C aryl glucosides; SGLT; Sodium dependent glucose co transporter; Urinary glucose

Indexed keywords

1 [5 CHLORO 4 (4 ETHYLBENZYL) 2 (3,4,5 TRIHYDROXY 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 2 YL)BENZYLOXY]PROPAN 2 ONE; 2 [2 (2 (ALLYLOXY)ETHYL) 4 CHLORO 5 (4 ETHYLBENZYL)PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [2 (ALLYLOXYMETHYL) 4 CHLORO 5 (4 ETHYLBENZYL)PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 2 [(2,2 DIFLUOROETHOXY)METHYL] 5 (4 ETHYLBENZYL)PHENYL] 6 (HYDROXYMETHYL) TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 2 [(2,2 DIFLUOROPROPOXY)METHYL] 5 (4 ETHYLBENZYL)PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHOXYBENZYL) 2 (2 METHOXYETHYL)PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL 2 [(2 HYDROXYPROPOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL) TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 (METHOXYMETHYL)PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 (PHENOXYMETHYL)PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [(2 FLUOROETHOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [(2 FLUOROPROPOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL) TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [(2 HYDROXYETHOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [(2 METHOXYETHOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL) TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [(2,2,2 TRIFLUOROETHOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [(3 HYDROXYPROPOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL) TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [(PROP 2 YNYLOXY)METHYL]PHENYL] 6 (HYDROXYMETHYL) TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [2 (PROP 2 YNYLOXY)ETHYL]PHENYL] 6 (HYDROXYMETHYL) TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; 2 [4 CHLORO 5 (4 ETHYLBENZYL) 2 [[2 (METHYLAMINO)PROPOXY]METHYL]PHENYL] 6 (HYDROXYMETHYL)TETRAHYDRO 2H PYRAN 3,4,5 TRIOL; GLUCOSE; GLUCOSIDE; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 1;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SYNTHESIS; GLUCOSE URINE LEVEL; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SUBSTITUTION REACTION; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CELL LINE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953139287     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.04.088     Document Type: Article

References (33)

1. Oku A., Ueta K., Arakawa K., Ishihara T., Nawano M., Kuronuma Y., Matsumoto M., Saito A., Tsujihara K., Anai M., Asano T., Kanai Y., and Endou H. Diabetes 48 (1999) 1794
2. Tsujihara K., Hongu M., Saito K., Kawanishi H., Kuriyama K., Matsumoto M., Oku A., Ueta K., Tsuda M., and Saito A. J. Med. Chem. 42 (1999) 5311
3. Arakawa K., Ishihara T., Oku A., Nawano M., Ueta K., Kitamura K., Matsumoto M., and Saito A. Br. J. Pharmacol. 132 (2001) 578
4. Hediger M.A., and Rhoads D.B. Physiol. Rev. 74 (1994) 993
5. Lee W.S., Kanai Y., Wells R.G., and Hediger M.A. J. Biol. Chem. 269 (1994) 12032
6. Kanai L., Lee W.S., You G., Brown D., and Hediger M.A. J. Clin. Invest. 93 (1994) 397
7. You G., Lee W.S., Barros E.J.G., Kanai Y., Huo T.L., Khawaja S., Wells R.G., Nigam S.K., and Heidiger M.A. J. Biol. Chem. 270 (1995) 29365
8. Isaji M. Curr. Opin. Invest. Drugs 8 (2007) 285
9. Washburn W.N. J. Med. Chem. 52 (2009) 1785
10. Washburn W.N. Expert Opin. Ther. Patents 19 (2009) 1485
11. Ohsumi K., Matsueda H., Hatanaka T., Hirama R., Umemura T., Oonuki A., Ishida N., Kageyama Y., Maezono K., and Kondo N. Bioorg. Med. Chem. Lett. 13 (2003) 2269
12. Dudash Jr. J., Zhang X., Zeck R.E., Johnson S.G., Cox G.G., Conway B.R., Rybczynski P.J., and Demarest K.T. Bioorg. Med. Chem. Lett. 14 (2004) 5121
13. Zhang X., Urbanski M., Patel M., Zeck R.E., Cox G.G., Bian H., Conway B.R., Rybczynski P.J., and Demarest K.T. Bioorg. Med. Chem. Lett. 15 (2005) 5202
14. Zhang X., Urbanski M., Patel M., Cox G.G., Zeck R.E., Bian H., Conway B.R., Beavers M.P., Rybczynski P.J., and Demarest K.T. Bioorg. Med. Chem. Lett. 16 (2006) 1696
15. Katsuno K., Fujimori Y., Takemura Y., Hiratochi M., Itoh F., Komatsu Y., Fujikura H., and Isaji M. J. Pharmacol. Exp. Ther. 320 (2007) 323
16. Fujimori Y., Katsuno K., Nakashima I., Ishikawa-Takemura Y., Fujikura H., and Isaji M. J. Pharmacol. Exp. Ther. 327 (2008) 268
17. Meng W., Ellsworth B.A., Nirschl A.A., McCann P.J., Patel M., Wu G., Sher P.M., Morrison E.P., Biller S.A., Zahler R., Deshpande P.P., Pullockaran A., Hagan D.L., Morgan N., Taylor J.R., Obermeier M.T., Humphreys W.G., Khanna A., Discenza L., Robertson J.G., Wang A., Han S., Wetterau J.R., Janovitz E.B., Flint O.P., Whaley J.M., and Washburn W.N. J. Med. Chem. 51 (2008) 1145
18. Han S., Hagan D.L., Taylor J.R., Xin L., Meng W., Biller S.A., Wetterau J.R., Washburn W.N., and Whaley J.M. Diabetes 57 (2008) 1723
19. Xu B., Lv B., Feng Y., Xu G., Du J., Welihinda A., Sheng Z., Seed B., and Chen Y. Bioorg. Med. Chem. Lett. 19 (2009) 5632
20. Lv B., Xu B., Feng Y., Peng K., Xu G., Du J., Zhang L., Zhang W., Zhang T., Zhu L., Ding H., Sheng Z., Welihinda A., Seed B., and Chen Y. Bioorg. Med. Chem. Lett. 19 (2009) 6877
21. Portions of this work have been published in the following patent application: Chen, Y.; Feng, Y.; Xu, B.; Lv, B.; Seed, B.; Hadd, M. J.; Chen, H.; Sheng, Z.; Xu, M.; Wang, C.; Du, J.; Zhang, L.; Xu, G.; Wu, Y. PCT Int. Appl. WO2008122014; Chem. Abstr. 2008, 149, 378967.
22. Czernecki S., and Ville G. J. Org. Chem. 54 (1989) 610
23. Bihovsky R., Selick C., and Giusti I. J. Org. Chem. 53 (1988) 4026
24. Lancelin J.M., Zollo P.H.A., and Sinay P. Tetrahedron Lett. 24 (1983) 4833
25. Benhaddou R., Czernecki S., Farid W., Ville G., Xie J., and Zegar A. Carbohydr. Res. 260 (1994) 243
26. Ellsworth B.A., Doyle A.G., Patel M., Caceres-Cortes J., Meng W., Deshpande P.P., Pullockaran A., and Washburn W.N. Tetrahedron: Asymmetry 14 (2003) 3243
27. Babirad S.A., Wang Y., and Kishi Y. J. Org. Chem. 52 (1987) 1370
28. Wang Y., Babirad S.A., and Kishi Y. J. Org. Chem. 57 (1992) 468
29. Viet N., Cheng X., and Morton T.H. J. Am. Chem. Soc. 114 (1992) 7127
30. Shiozaki M., and Kobayashi Y. Tetrahedron: Asymmetry 3 (1992) 451
31. Muñoz M.P., Adrio J., Carretero J.C., and Echavarren A.M. Organometallics 24 (2005) 1293
32. Lee G.H., Choi E.B., Lee E., and Pak C.S. J. Org. Chem. 59 (1994) 1428
33. 50 value of 6.7 nM and 130-fold selectivity for hSGLT2 were observed. See Section 4.2 for further details on the in vitro experimental methods used in this paper.